Vaxart (NASDAQ:VXRT) stock jumped 37.9% premarket after the company reported positive early-stage data for its ...

Vaxart's (VXRT) shares soar 37% after positive early trial results for its oral norovirus vaccine. Read more here.

USA-based biotech Vaxart has reported positive top-line results from a Phase I trial comparing its second-generation oral ...

SOUTH SAN FRANCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its ...

SOUTH SAN FRANCISCO - Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company with a market capitalization of approximately $90 million and shares down nearly 49% over the past year ...

Investing.com -- Vaxart Inc (NASDAQ: VXRT) stock surged 70% after the clinical-stage biotechnology company reported positive topline results from its Phase 1 trial evaluating second-generation ...

A California-based biotech company stole the show on Wednesday after the company reported positive clinical data ...

Story March 21 - Vaxart: The South San Francisco-based company has laid off 10% of its staff after the U.S. government unexpectedly ordered the biotech stop work on a trial of its COVID-19 vaccine ...

Vaxart said in November it had completed enrolment in a phase 1 trial of its oral COVID-19 vaccine VXA-CoV2-1, having reported viral load reduction and antibody responses in a COVID-19 hamster ...

Vaxart, and VaxInnate. mRNA vaccine heavyweights Pfizer/BioNTech and Moderna, meanwhile, are working on novel shots for flu, although, they are initially focusing their efforts on multivalent ...